TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04239833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 tablets
Description: The initial dose of SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo SH-1028 tablets
Description: The initial dose of Placebo SH-1028 tablets is 200 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.~Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label SH-1028 tablets (crossover to active SH-1028 tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gefitinib
Description: The initial dose of Gefitinib is 250 mg once daily . A cycle of treatment is defined as 21 days of once daily treatment.
Study: NCT03314688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary/Physical Activity intervention
Description: Motivational counseling to follow established dietary and exercise guidelines.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
Study: NCT01305122

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neurocognitive tests
Description: * inclusion~* 1 year~* 3 years~* 5 years
Study: NCT02109250

Intervention type: DRUG
Intervention: Caprelsa
Description: Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
Study: NCT03328676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
Study: NCT00725803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450
Description: GS-9450 capsules administered orally once daily
Study: NCT00511420

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa product type 4
Description: 6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
Study: NCT02237690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin hydrochloride liposome
Description: 50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin hydrochloride liposome
Description: 50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
Study: NCT01472484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8x87 white
Description: 2 x 50 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8x87 brown
Description: 2 x 50 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BAT 881
Description: 2 x 50 g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 586/8
Description: 2 x 50 g
Study: NCT03341884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: A single oral dose of 100 mg ipatasertib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: A single oral dose of 100 mg ipatasertib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: A single oral dose of 100 mg ipatasertib will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: A single oral dose of 100 mg ipatasertib will be administered.
Study: NCT02840136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam combination product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Study: NCT01412229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
Study: NCT01554657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 Days of Antibiotics
Description: The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 7 Days of Antibiotics therapy for pneumonia
Description: The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
Study: NCT01672957

Intervention type: DRUG
Intervention: Mycophenolate Mofetil
Description: Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.

Intervention type: DRUG
Intervention: Immunosuppressive Therapy
Description: Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
Study: NCT00725803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9450 Placebo
Description: Placebo to match GS-9450 administered orally once daily
Study: NCT02453386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozadenant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tozadenant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02285894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory hold
Description: Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
Study: NCT02371343

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil, Ocean plus
Description: Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower Oil
Study: NCT03703791

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AR101
Description: AR101 powder
Study: NCT01523470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIPAP Synchrony
Description: BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP Synchrony
Description: BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
Study: NCT01924429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Escalating stepped dose titration: 30, 50 or 70mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine
Description: Escalating stepped dose titration: 30, 50 or 70mg
Study: NCT04109339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: During the laparoscopic hysteromyomectomia operation, different doses of oxytocin was used with different routs.
Study: NCT00954252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 1x, oral capsule, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 2x, oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 4x, oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 8x, oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 16x, oral capsule, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5074
Description: 24x, oral capsule, single dose
Study: NCT01779271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelubiprofen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Study: NCT00184171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide 9 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth mixture

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fiber
Description: Fiber for control
Study: NCT01821573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: Experimental arm group:~* 150 Units in rectus femoris ( 3 ml and 3 points)~* 70 units in medial gastrocnemius (1.4 ml and 1 point)~* 70 units in lateral gastrocnemius ( 1.4 ml and 1 point)~* 60 units in soleus ( 1.2 ml and 3 points)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: injection of NaCl 0.9%
Description: Placebo comparator group: injection of NaCl 0.9%:~* 3 ml of NaCl 0.9% in rectus femoris in 3 points~* 1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point~* 1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point~* 1.2 ml of NaCl 0.9% in soleus in 3 points
Study: NCT01465685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: capsules identical to MDMA or methylphenidate
Study: NCT01226121

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridial collagenase injectable
Description: Finger manipulation performed 1, 2, or 4 days following collagenase injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridial collagenase injectable
Description: Finger manipulation performed 1, 2, or 4 days following collagenase injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridial collagenase injectable
Description: Finger manipulation performed 1, 2, or 4 days following collagenase injection
Study: NCT04592484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDK-002
Description: CDK-002 administered intratumorally
Study: NCT00535574

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bexarotene (Targretin LGD1069)
Description: 75 mg per day for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bexarotene (Targretin LGD1069)
Description: 75 mg per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bexarotene
Description: 75 mg/day 6 weeks
Study: NCT03627390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C1
Description: BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.07 mL/kg) intramuscularly once daily for 32 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: BP-C2, 0.15% solution for oral use; 15 ml orally once daily for 32 consecutive days
Study: NCT03314246

Intervention type: OTHER
Group type: OTHER
Intervention: FAST
Description: Fasting Algorithm for Singaporeans with Type 2 Diabetes

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study: NCT02203175

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Before the anesthesia induction, 5 ml isotonic saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl
Description: before the anesthesia induction 50 mcgr fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: before the anesthesia induction 50 mcgr fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propofol
Description: during anesthesia 50 mg proposal with 50 mcgr fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: during anesthesia 50 mg proposal with 50 mcgr fentanyl
Study: NCT00773045

Intervention type: OTHER
Intervention: A Pain training program and pain measurement
Description: Comparing patients treated with and without analgesia and sedation protocol
Study: NCT01253707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 337
Description: AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
Study: NCT01051089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Exercise and diet education
Study: NCT04371796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab injection
Description: Sintilimab injection 200mg, 2cycles of treatment before surgery
Study: NCT01557790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation Therapy
Study: NCT01439815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate Nasal Spray
Description: two sprays in each nostril once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: two sprays in each nostril once daily
Study: NCT04125251

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Skills Building Training
Description: The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life Skills Building Training
Description: The Life Skills Building intervention is a curriculum based on 10-12 sessions. The sessions will include the skills essential for family harmony and improving overall mental health of the participants
Study: NCT00642642

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (azficel-T)
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart.
Study: NCT02233478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice alone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice alone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice alone

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soybean Flour Protein
Description: Soybean Flour Protein combined with Pomegranate Juice

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy Isolate Protein
Description: Soy Isolate Protein combined with Pomegranate Juice
Study: NCT01496937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0974

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG0974
Study: NCT02622997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with first flocked swab
Description: Cervico-vaginal self-sample taken with first flocked swab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with a second flocked swab
Description: Cervico-vaginal self-sample taken with a second flocked swab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervico-vaginal self-sample taken with a HerSwab device
Description: Cervico-vaginal self-sample taken with a HerSwab device
Study: NCT00642642

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of 3 mm post auricular skin punch biopsies.~2. Administration of 3 study treatments administered 14 ± 7 days apart.
Study: NCT03478384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient coaching
Description: Patients receive regular coaching to test if the coaching alters their perceived self-efficacy.
Study: NCT00404092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caspofungin
Description: i.v.
Study: NCT04278274

Intervention type: PROCEDURE
Intervention: artificial intelligence prediction system
Description: The tumor ROI in the post- neoadjuvant treatment MRI images will be manually delineated, and further subjected to the AI prediction system arm to verify the predictive accuracy of this AI prediction system in identifying the pCR individuals from non-pCR patients with LARC.
Study: NCT04548141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Scoring of the IPAQ is performed according to references. Scoring of the SAPHIR has been submitted for copyright protection (involves a series of 23 additions)
Study: NCT01557712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine venlafaxine
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of ketamine~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:~* Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)~* D0 to D4: 75 mg of venlafaxine~* D4 to D14: 150 mg per day of venlafaxine~* D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder
Study: NCT04278274

Intervention type: PROCEDURE
Intervention: the radiologists
Description: The enrolled patients will be assigned to the trained experienced radiologists to evaluate their predictive accuracy in identifying the pCR individuals from non-pCR patients
Study: NCT01447212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone, Injectable
Description: Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
Study: NCT00850174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: 600 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trileptal®
Description: 600 mg Tablet
Study: NCT01020396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Vaginal Gel, 0.75%